Windlas Biotech Share Price Target 2026 Analyst Forecast Bull and Bear Case

Windlas Biotech (NSE: WINDLAS) is a Contract Development and Manufacturing CDMO company trading at Rs 859 with a market capitalisation of Rs 1,775 crore. Analysts have set the Windlas Biotech share price target at Rs 1,050 for 2026, based on FY27 earnings projections and sector re-rating potential. According to Kunal Singla, Senior Research Analyst at Univest, the Rs 1,050 price objective reflects improving fundamentals in the Contract Development and Manufacturing CDMO space. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Windlas Biotech Share Price Target 2026: Key Takeaways

• Windlas Biotech share price target 2026: Rs 1,050 (20% upside from CMP Rs 859)
• Bull case: Rs 1,250 | Bear case: Rs 685
• Ticker: WINDLAS | Sector: Contract Development and Manufacturing CDMO | MCap: Rs 1,775 crore
• 52W range: Rs 697.4 to Rs 1,098 | PE: 18x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Windlas Biotech Company Overview

Windlas Biotech (NSE: WINDLAS) is a Dehradun-based pharmaceutical CDMO providing formulation development, clinical batch manufacturing, and commercial scale manufacturing of solid dosage forms for domestic and regulated market clients. At CMP Rs 859 against a 52 week range of Rs 697.4 to Rs 1,098, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 1,775 crore with trailing PE of 18x. Compared to peers in pharma CDMO like Divi’s Laboratories and Suven Pharmaceuticals, Windlas Biotech is positioned as a potential re-rating candidate toward the Rs 1,050 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	WINDLAS
Sector	Contract Development and Manufacturing CDMO
CMP (2026)	Rs 859
52 Week High	Rs 1,098
52 Week Low	Rs 697.4
Market Cap	Rs 1,775 crore
Trailing PE	18x
12-Month Analyst Target	Rs 1,050
Bull Case Target	Rs 1,250
Bear Case Target	Rs 685

Why Is the Windlas Biotech Share Price Target Set at Rs 1,050 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Windlas Biotech share price target of Rs 1,050 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Kunal Singla at Univest notes that Q4 FY26 results confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 859.

Structural Sector Tailwinds in Contract Development and Manufacturing CDMO

The Contract Development and Manufacturing CDMO sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Windlas Biotech’s position among peers in pharma CDMO like Divi’s Laboratories and Suven Pharmaceuticals creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 1,250 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Windlas Biotech’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,050 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Windlas Biotech’s Contract Development and Manufacturing CDMO operations, improving the probability of achieving the Rs 1,050 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 18x PE, Windlas Biotech is positioned as a beneficiary of institutional reallocation toward the Rs 1,250 bull case over the medium term.

Windlas Biotech Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Windlas Biotech Share Price Target

Near-term support for Windlas Biotech is anchored close to the 52 week low of Rs 697.4. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 859.

12-Month Windlas Biotech Share Price Target 2026

The 12-month Windlas Biotech share price target 2026 is Rs 1,050, implying approximately 20 percent upside from CMP Rs 859. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Windlas Biotech Share Price Target: FY27 to FY28

The long term Windlas Biotech share price target for FY27 to FY28 is Rs 1,250 in the bull case, requiring full earnings delivery, re-rating among peers in pharma CDMO like Divi’s Laboratories and Suven Pharmaceuticals, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Windlas Biotech in 2026

Bull Case Windlas Biotech Share Price Target: Rs 1,250

The bull case Windlas Biotech share price target of Rs 1,250 materialises when FY27 earnings beat analyst estimates, Contract Development and Manufacturing CDMO tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 859.

Bear Case Windlas Biotech Share Price Target: Rs 685

The bear case Windlas Biotech share price target of Rs 685 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 697.4.

Scenario	Target	Key Conditions
Bull Case	Rs 1,250	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 1,050	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 685	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Windlas Biotech 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Windlas Biotech share price target of Rs 1,050, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,050 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Contract Development and Manufacturing CDMO Peers

Intensifying competition from peers in pharma CDMO like Divi’s Laboratories and Suven Pharmaceuticals could compress Windlas Biotech’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,050 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Windlas Biotech

Check the Univest Screener for live data

Before considering any investment based on the Windlas Biotech share price target of Rs 1,050, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Contract Development and Manufacturing CDMO sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Windlas Biotech (NSE: WINDLAS) with full regulatory protection. Study the competitive landscape among peers in pharma CDMO like Divi’s Laboratories and Suven Pharmaceuticals before executing any position.

Plan your entry using the 52 week low of Rs 697.4 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,050 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Windlas Biotech’s live share price and receive daily stock recommendations.

FAQs on Windlas Biotech Share Price Target 2026

What is the Windlas Biotech share price target for 2026?

Ans. The Windlas Biotech share price target 2026 is Rs 1,050, implying approximately 20 percent upside from CMP Rs 859. Bull case is Rs 1,250, bear case is Rs 685.

What was the Windlas Biotech share price target for 2025?

Ans. The 2025 price objective for Windlas Biotech was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,050, reflecting FY27 growth potential from CMP Rs 859.

Is Windlas Biotech a good investment at Rs 859?

Ans. At Rs 859, Windlas Biotech offers potential upside toward Rs 1,050 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Windlas Biotech share price target 2026?

Ans. Key risks to the Windlas Biotech share price target of Rs 1,050 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Contract Development and Manufacturing CDMO. Monitoring quarterly results is essential.

What is the 52 week high and low of Windlas Biotech?

Ans. The 52 week high of Windlas Biotech is Rs 1,098 and the 52 week low is Rs 697.4. At CMP Rs 859, the stock offers potential upside toward the Rs 1,050 price objective.

What are the main growth catalysts for Windlas Biotech in 2026?

Ans. Key catalysts include FY27 PAT recovery, Contract Development and Manufacturing CDMO tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Windlas Biotech compare to its peers?

Ans. Windlas Biotech operates in Contract Development and Manufacturing CDMO alongside peers in pharma CDMO like Divi’s Laboratories and Suven Pharmaceuticals. At CMP Rs 859 with MCap Rs 1,775 crore, it is a potential re-rating candidate toward the Windlas Biotech share price target of Rs 1,050 on FY27 delivery.

What is the Windlas Biotech share price target for 2027?

Ans. The long-term Windlas Biotech share price target for FY27 to FY28 is Rs 1,250 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.